120
Participants
Start Date
May 26, 2023
Primary Completion Date
April 26, 2025
Study Completion Date
July 31, 2026
total neoadjuvant therapy
All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
Hospital Universitario 12 de Octubre, Madrid
Hospital Germans Trias i Pujol - ICO Badalona, Badalona
Hospital Universitari Mutua de Terrassa, Terrassa
H. de la Santa Creu i Sant Pau, Barcelona
H.U. Vall d'Hebron, Barcelona
Hospital Clínic, Universitat de Barcelona, Barcelona
Hospital Del Mar, Barcelona, Barcelona
Hospital Sant Joan Despí - Moisés Broggi., Barcelona
ICO-Hospitalet, Barcelona
ICO Girona, Girona
H. Univeristario La Paz, Madrid
Hospital Quirón Salud Valencia, Valencia
Hospital Universitari i Politècnic La Fe, Valencia
Hospital Clínico Universitario Lozano Blesa, Zaragoza
Hospital Universitario Miguel Servet, Zaragoza
Grupo Espanol Multidisciplinario del Cancer Digestivo
OTHER